CETN3: A Potential Drug Target for Neurological Disorders (G1070)

Target Name: CETN3

NCBI ID: G1070

CETN3

CETN3: A Potential Drug Target for Neurological Disorders

CETN3 (CETN3 variant 2) is a protein that is expressed in the brain and is involved in the regulation of cell survival and proliferation. It is a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

The CETN3 gene was first identified in 2008 and has since been shown to be involved in the regulation of several cellular processes, including cell adhesion, migration, and survival. CETN3 has also been shown to play a role in modulating the activity of several signaling pathways, including the TGF-β pathway and the Wnt pathway.

One of the most promising aspects of CETN3 is its potential as a drug target. The CETN3 protein has been shown to be involved in the regulation of several neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. In particular, studies have shown that CETN3 is involved in the development and progression of these disorders, and that modulating its activity may be a promising approach to treating these conditions.

For example, research has shown that CETN3 is involved in the development of neurodegeneration in Alzheimer's disease. Studies have shown that individuals with the CETN3 variant have higher levels of the protein than those without the variant, and that these individuals are more likely to develop neurodegeneration than those without the variant. Additionally, modulating CETN3 activity has been shown to be a potential approach to treating Alzheimer's disease, with researchers focusing on using small molecules to inhibit its activity.

CETN3 has also been shown to be involved in the regulation of Parkinson's disease, a disorder that is characterized by the loss of motor and cognitive function in middle-aged and older individuals. Studies have shown that individuals with the CETN3 variant have lower levels of the protein than those without the variant, and that these individuals are more likely to develop Parkinson's disease than those without the variant. Additionally, modulating CETN3 activity has been shown to be a potential approach to treating Parkinson's disease, with researchers focusing on using small molecules to inhibit its activity.

CETN3 has also been shown to be involved in the regulation of depression, a disorder that is characterized by persistent feelings of sadness and hopelessness. Studies have shown that individuals with the CETN3 variant have higher levels of the protein than those without the variant, and that these individuals are more likely to experience symptoms of depression than those without the variant. Additionally, modulating CETN3 activity has been shown to be a potential approach to treating depression, with researchers focusing on using small molecules to inhibit its activity.

In conclusion, CETN3 is a protein that is involved in the regulation of cell survival and proliferation and has been shown to play a role in the development and progression of several neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. As such, CETN3 is a promising target for drug development, with researchers focusing on modulating its activity to treat these disorders. Further research is needed to fully understand the role of CETN3 in these conditions and to develop safe and effective treatments.

Protein Name: Centrin 3

Functions: Plays a fundamental role in microtubule-organizing center structure and function

The "CETN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CETN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets